Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug

Arrowhead Pharma Shares Soar on Early Liver Data for RNAi Drug

Source: 
Xconomy
snippet: 

An Arrowhead Pharmaceuticals drug for a rare liver disease now has early Phase 2 results and the data so far look good. Not only did the therapy reduce levels of a mutant protein associated with the disorder, but patients also showed improvements in several biological measures of liver injury.